Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568534 | 0.98 | OPRM1 (0.38) | OPRM1OPRL1LMNATSHRCYP19A1 | |
| SCHEMBL18562128 | 0.78 | OPRM1 (0.40) | OPRM1OPRL1LMNATSHRKMT2A | |
| SCHEMBL13992820 | 0.74 | LMNA (0.37) | LMNATSHRCYP19A1CA1CA2 | |
| SCHEMBL13992824 | 0.72 | LMNA (0.36) | LMNATSHRCYP19A1CA1CA2 | |
| SCHEMBL15763622 | 0.71 | TRIM24 (0.39) | LMNATSHRCYP19A1CA1CA2 | |
| SCHEMBL6509519 | 0.71 | OPRM1 (0.36) | OPRM1OPRL1 | |
| SCHEMBL17438541 | 0.70 | OPRM1 (0.36) | OPRM1OPRL1 | |
| SCHEMBL6132212 | 0.69 | LMNA (0.34) | LMNATSHRCYP19A1CA1CA2 | |
| SCHEMBL17438634 | 0.69 | OPRM1 (0.48) | OPRM1OPRL1 | |
| SCHEMBL21535361 | 0.68 | LMNA (0.44) | OPRM1OPRL1LMNATSHRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | GRUENENTHAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| EP-3169665-B1 | SUBSTITUTED AZA-SPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-05-09 | — | — | EP | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3169665-A1 | SUBSTITUTED AZA-SPIRO(4.5)DECAN-DERIVATIVES | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| EP-3169666-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016008583-A1 | SUBSTITUTED AZA-SPIRO(4.5)DECAN-DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016008582-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2121689-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-8404740-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20100048554-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-2121689-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008101659-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048554-A1 | Spirocyclic Cyclohexane Compounds | OPRL1, OPRD1, OPRK1 | OPRM1 4/4885OPRL1 1/4885LMNA 1724/4885 |
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885LMNA 3500/4885 |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | OPRM1 2/4885OPRL1 1/4885LMNA 3683/4885 |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885LMNA 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.